Literature DB >> 20854191

Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models.

Xi-Ling Jiang1, Frank J Gonzalez, Ai-Ming Yu.   

Abstract

Determining the in vivo significance of a specific enzyme, transporter, or xenobiotic receptor in drug metabolism and pharmacokinetics may be hampered by gene multiplicity and complexity, levels of expression, and interaction between various components involved. The development of knockout (loss-of-function) and transgenic (gain-of-function) mouse models opens the door to the improved understanding of gene function in a whole-body system. There is also growing interest in the development of humanized mice to overcome species differences in drug metabolism and disposition. This review, therefore, aims to summarize and discuss some successful examples of drug-metabolizing enzyme, transporter, and nuclear-receptor genetically modified mouse models. These genetically modified mouse models have been proven as invaluable models for understanding in vivo function of drug-metabolizing enzymes, transporters, and xenobiotic receptors in drug metabolism and transport, as well as predicting potential drug-drug interaction and toxicity in humans. Nevertheless, concerns remain about interpretation of data obtained from such genetically modified mouse models, in which the expression of related genes is altered significantly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854191      PMCID: PMC3025535          DOI: 10.3109/03602532.2010.512294

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  139 in total

1.  Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation.

Authors:  Y M Qian; X J Sun; M H Tong; X P Li; J Richa; W C Song
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

2.  Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.

Authors:  J W Jonker; E Wagenaar; C A Mol; M Buitelaar; H Koepsell; J W Smit; A H Schinkel
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase.

Authors:  Anna L Shen; Kathleen A O'Leary; Charles B Kasper
Journal:  J Biol Chem       Date:  2001-12-12       Impact factor: 5.157

4.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

Authors:  J Corchero; C P Granvil; T E Akiyama; G P Hayhurst; S Pimprale; L Feigenbaum; J R Idle; F J Gonzalez
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

5.  Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.

Authors:  R Zwart; S Verhaagh; M Buitelaar; C Popp-Snijders; D P Barlow
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice.

Authors:  Douglas H Sweet; David S Miller; John B Pritchard; Yuko Fujiwara; David R Beier; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

7.  Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus.

Authors:  Ryoichi Fujiwara; Nghia Nguyen; Shujuan Chen; Robert H Tukey
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

8.  A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.

Authors:  Hongliang Cai; Nghia Nguyen; Vincent Peterkin; Young-Sun Yang; Kathy Hotz; Deirdre Beaton La Placa; Shujuan Chen; Robert H Tukey; Jeffrey C Stevens
Journal:  Drug Metab Dispos       Date:  2010-02-02       Impact factor: 3.922

9.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Authors:  Chao Wu; Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2009-05-13       Impact factor: 5.858

10.  Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model.

Authors:  Xin Zhou; Xiaoliang Zhuo; Fang Xie; Kerri Kluetzman; Yue-Zhong Shu; W Griffith Humphreys; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2009-11-18       Impact factor: 4.030

View more
  13 in total

Review 1.  Emerging applications of metabolomics in studying chemopreventive phytochemicals.

Authors:  Lei Wang; Chi Chen
Journal:  AAPS J       Date:  2013-06-22       Impact factor: 4.009

Review 2.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  Clinical pharmacokinetics and pharmacodynamics of clopidogrel.

Authors:  Xi-Ling Jiang; Snehal Samant; Lawrence J Lesko; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

4.  Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants.

Authors:  Feifeng Song; Yongjun Hu; Huidi Jiang; David E Smith
Journal:  Drug Metab Dispos       Date:  2016-11-11       Impact factor: 3.922

5.  Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2011-04-04       Impact factor: 3.922

6.  Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration.

Authors:  Matthew E Albertolle; Thanh T N Phan; Ambra Pozzi; F Peter Guengerich
Journal:  Mol Cell Proteomics       Date:  2018-01-26       Impact factor: 5.911

7.  New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.

Authors:  Abhinav Bhushan; Nicole J Martucci; O Berk Usta; Martin L Yarmush
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-03-21       Impact factor: 4.481

8.  Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-02-07       Impact factor: 3.922

Review 9.  The safety evaluation of food flavouring substances: the role of metabolic studies.

Authors:  Robert L Smith; Samuel M Cohen; Shoji Fukushima; Nigel J Gooderham; Stephen S Hecht; F Peter Guengerich; Ivonne M C M Rietjens; Maria Bastaki; Christie L Harman; Margaret M McGowen; Sean V Taylor
Journal:  Toxicol Res (Camb)       Date:  2018-03-28       Impact factor: 3.524

Review 10.  LC-MS-based Metabolomics of Xenobiotic-induced Toxicities.

Authors:  Chi Chen; Sangyub Kim
Journal:  Comput Struct Biotechnol J       Date:  2013-03-12       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.